NorthRock Partners LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

NorthRock Partners LLC decreased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 10.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,387 shares of the company’s stock after selling 3,323 shares during the quarter. Johnson & Johnson makes up 0.5% of NorthRock Partners LLC’s portfolio, making the stock its 26th biggest holding. NorthRock Partners LLC’s holdings in Johnson & Johnson were worth $4,474,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Morton Brown Family Wealth LLC grew its position in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $39,000. First Bank & Trust grew its position in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares in the last quarter. Heritage Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $84,000. Finally, Timber Creek Capital Management LLC grew its position in shares of Johnson & Johnson by 225.0% during the third quarter. Timber Creek Capital Management LLC now owns 650 shares of the company’s stock worth $106,000 after purchasing an additional 450 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $168.31 on Wednesday. The firm has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The business has a 50 day simple moving average of $175.98 and a 200-day simple moving average of $171.06. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same period last year, the company earned $2.13 EPS. Johnson & Johnson’s quarterly revenue was down 4.4% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on JNJ shares. Atlantic Securities cut their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Credit Suisse Group began coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Citigroup raised their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, Raymond James cut their price target on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Insider Buying and Selling

In related news, EVP Ashley Mcevoy sold 73,323 shares of the firm’s stock in a transaction that occurred on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the sale, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The disclosure for this sale can be found here. In the last three months, insiders sold 233,611 shares of company stock valued at $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.